Effects of combined behavioral intervention and tolterodine on patient-reported outcomes

Canadian Journal of Urology

Volumn 17, Issue 4, 2010, Pages 5283-5290

  Wyman, Jean F ^a   Klutke, Carl ^b   Burgio, Kathryn ^c   Guan, Zhonghong ^d   Sun, Franklin ^d   Berriman, Sandra ^d   Bavendam, Tamara ^d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d PFIZER INC   (United States)

Author keywords

Antimuscarinic; Behavioral intervention; Combination therapy; Overactive bladder; Patient reported outcomes; Urgency urinary incontinence

Indexed keywords

BENZHYDRYL DERIVATIVE; CRESOL; MUSCARINIC RECEPTOR BLOCKING AGENT; PHENYLPROPANOLAMINE; TOLTERODINE;

ADULT; AGED; ARTICLE; BEHAVIOR THERAPY; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; OVERACTIVE BLADDER; PATIENT SATISFACTION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BEHAVIOR THERAPY; BENZHYDRYL COMPOUNDS; COMBINED MODALITY THERAPY; CRESOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PATIENT SATISFACTION; PHENYLPROPANOLAMINE; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; YOUNG ADULT;

EID: 79952052663     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Abrams P, Artibani W, Cardozo L, Dmochowski R, van Kerrebroeck P, Sand P. Reviewing the ICS 2002 Terminology Report: the ongoing debate. Neurourol Urodyn 2006;25(3):293.
2. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003;61(1):37-49.
3. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50(6):1306-1315.
4. Brown JS, Mcghan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000;6(11 suppl):574-579.
5. Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008;101(11):1388-1395.
6. Andersson K-E. Antimuscarinics for the treatment of overactive bladder. Lancet Neurol 2004;3(1):46-53.
7. Burgio KL. Current perspectives on management of urgency using bladder and behavioral training. J Am Acad Nurse Pract 2004;16(10 Suppl):4-7.
8. Burgio KL. Behavioral treatment options for urinary incontinence. Gastroenterology 2004;126(1 Suppl 1):S82-S89.
9. Wyman JF, Fantl JA, Mcclish DK, Bump RC. Comparative efficacy of behavioral interventions in the management of female urinary incontinence. Continence Program for Women Research Group. Am J Obstet Gynecol 1998;179(4):999-1007.
10. Wyman JF, Burgio KL, Newman DK. Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence. Int J Clin Pract 2009;63(8):1177-1191.
11. Milne JL. Behavioral therapies for overactive bladder: making sense of the evidence. J Wound Ostomy Cont Nurs 2008;35(1):93-101.
12. Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc 2000; 48(4):370-374.
13. Mattiasson A, Blaakaer J, Hoye K, Wein AJ. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. BJU Int 2003;91(1):54-60.
14. Herschorn S, Becker D, Miller E, Thompson M, Forte L. Impact of a health education intervention in overactive bladder patients. Can J Urol 2004;11(6):2430-2437.
15. Klutke CG, Burgio KL, Wyman JF et al. Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication. J Urol 2009;181:2599-2607.
16. Abrams P, Artibani W, Gajewski JB, Hussain I. Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology 2006;68(suppl 2A):17-28.
17. Coyne KS, Elinoff V, Gordon DA et al. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine. Int J Clin Pract 2008;62(6):925-931.
18. Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the Patient Perception of Bladder Condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006;49(6):1079-1086.
19. Pleil AM, Coyne KS, Reese PR, Jumadilova Z, Rovner ES, Kelleher CJ. The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue-- the BSW. Value Health 2005;8(suppl 1):S25-S34.
20. Coyne KS, Tubaro A, Brubaker L, Bavendam T. Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts. Urology 2006;68(2 Suppl) 9-16.
21. Cardozo L, Coyne KS, Versi E. Validation of the urgency perception scale. BJU Int 2005;95:591-596.
22. Coyne K, Revicki D, Hunt T et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002;11(6):563-574.
23. Coyne KS, Matza LS, Thompson CL, Kopp ZS, Khullar V. Determining the importance of change in the overactive bladder questionnaire. J Urol 2006;176(2):627-632.
24. Bing MH, Moller LA, Jennum P, Mortensen S, Skovgaard LT, Lose G. Prevalence and bother of nocturia, and causes of sleep interruption in a Danish population of men and women aged 60-80 years. BJU Int 2006;98(3):599-604.
25. Burgio KL, Kraus SR, Menefee S et al. Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial. Ann Intern Med 2008;149(3):161-169.
26. Chancellor MB, Kianifard F, Beamer E, Mongay L, Ebinger U, Hicks G et al. A comparison of the efficacy of darifenacin alone vs. darifenacin plus a behavioural modification programme upon the symptoms of overactive bladder. Int J Clin Pract 2008; 62(4):606-613.